We tested in vitro 49 isolates of Chlamydia pneumoniae obtained from 35 children with community-acquired pneumonia against clarithromycin and erythromycin. The children were part of a treatment study comparing the two drugs. Clarithromycin was 2-to 10-fold more active than erythromycin, with a MIC for 90%6 of strains tested and minimal chlamydiacidal concentration for 90%Yo of strains tested of 0.031 ,ig/ml compared with 0.125 ,ug/ml for erythromycin. Eight of these children, two of whom were treated with erythromycin and six of whom received clarithromycin, remained culture positive after treatment. We were able to test 21 isolates from these children. All were susceptible to both drugs, and the MICs did not change after therapy.
Chlamydia pneumoniae is emerging as a frequent cause of community-acquired respiratory tract infection in adults and children, including pneumonia and bronchitis (3, 4, 7) . There are limited data on the treatment of these infections, because most studies have used serology only, and thus microbiologic efficacy could not be assessed. As part of a nationwide, multicenter study comparing clarithromycin and erythromycin suspensions for the treatment of community-acquired pneumonia in children 3 through 12 years of age, we isolated C. pneumoniae from 42 (16%) of the 260 children enrolled (7) . Although all of the children with C. pneumoniae infection improved clinically and radiographically, 9 (21%) of these children remained culture positive after treatment. C. pneumoniae was eradicated from 15 of 19 (79%) evaluable patients who were treated with clarithromycin and 12 of 14 (86%) of those treated with erythromycin. The dosages of clarithromycin and erythromycin suspensions were 15 and 40 mg/kg of body weight per day, respectively, both given in two divided doses for 10 days. We performed in vitro susceptibility testing against clarithromycin and erythromycin with isolates of C. pneumoniae from these children.
MATERIALS AND METHODS
Clarithromycin (Abbott Laboratories, North Chicago, Ill.) and erythromycin (Eli Lilly and Co., Indianapolis, Ind.) were supplied as powders and solubilized according to the instructions of the manufacturers.
The C. pneumoniae isolates were originally isolated from nasopharyngeal swab specimens cultured in cycloheximidetreated HEp-2 cells (1). Patient isolates were passed three to four times in tissue culture in antibiotic-free medium.
Susceptibility testing of C. pneumoniae was performed with cell culture of HEp-2 cells grown in 96-well microtiter plates (6) . Each well was inoculated with 0.2 ml of the organism diluted to yield 103 inclusion-forming units/ml and centrifuged at 2,000 x g for 1 h. The wells were then aspirated and overlayed with 0.2 ml of medium (Iscove's modified Dulbecco's medium [GIBCO]) containing 1 ,ug of cycloheximide per ml and serial twofold dilutions of the test drug. After incubation at 35°C for 72 h, cultures were fixed and stained for inclusions with fluorescein-conjugated antibody to the lipopolysaccharide genus antigen (Pathfinder Chlamydia Culture Confirmation System; Kallestad Diagnostics, Chaska, Minn.).
The MIC was the lowest antibiotic concentration at which no inclusions were seen. The minimal chlamydiacidal concentration (MCC) was determined by freezing the cultures at -70°C and then thawing them, passing the disrupted cell monolayers onto new cells, incubating them for 72 h, and then fixing and staining them as described above. The MCC was the lowest antibiotic concentration which resulted in no inclusions after passage. All tests were run in triplicate.
RESULTS
We were able to retrieve 49 isolates from 35 of the 42 children with pneumonia who had positive C. pneumoniae cultures; the MICs and MCCs are shown in Table 1 . Overall, clarithromycin was 2-to 10-fold more active than erythromycin, with a MIC for 90% of the strains tested (MIC90) and MCC for 90% of the strains tested (MCC9O) of 0.031 ,ug/ml compared with 0.125 ,ug/ml for erythromycin. Twenty-four of the C. pneumoniae-positive children were treated with clarithromycin, and 18 were treated with erythromycin. Nine of the children with C. pneumoniae infection remained culture positive after treatment; seven of these children were treated with clarithromycin and two received erythromycin. We were able to retrieve 21 isolates from eight of these patients, including two children who were treated with erythromycin and six who received clarithromycin. Both antibiotics were given for 10 days. The isolates were obtained at the baseline visit before treatment, within 48 h after the end of treatment, and 4 to 6 weeks after treatment. The MICs for these isolates are shown in Table 2 . All of these isolates were susceptible to both antibiotics, and the MICs did not change during or after therapy. Despite the persistence of C. pneumoniae, all of these patients improved clinically with complete resolution of the infiltrates shown on their chest radiographs. due to C. pneumoniae. Several of the original patients with C. pneumoniae infection reported by Grayston et al. (4) were thought to have infection with Mycoplasma pneumoniae and were treated with erythromycin (1 g/day for 5 to 10 days). Many of these patients did not appear to respond because they had continuing or recurring symptoms; however, follow-up cultures were not done. We have observed several patients with C. pneumoniae infection who have been persistently culture positive and symptomatic despite 7-to-30-day courses of doxycycline and tetracycline treatment (5). Although resistance of C. trachomatis to tetracycline and erythromycin has been reported in vitro, the relationship to treatment failure is (6) . Clarithromycin has excellent tissue and intracellular penetration, especially into bronchial epithelium and alveolar macrophages (2). These observations suggest that clarithromycin should be superior to erythromycin for the treatment of respiratory infections due to C. pneumoniae; however, the results of the pediatric pneumonia treatment study suggest that the two drugs are equivalent in terms of eradicating C. pneumoniae from the respiratory tract (1) . These data also infer that performance in vitro may not predict microbiologic efficacy in vivo. Even though the organism persisted after treatment in nine patients, they all improved clinically. The results of this study suggest that persistence of C. pneumoniae in these patients was not secondary to the development of antibiotic resistance.
